Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
Summary of "Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone."
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. The short- and long-term metabolic safety of sertindole was compared to that of risperidone in a subset of patients enrolled in the sertindole cohort prospective (SCoP) study, an open randomized study. In 261 randomized patients, there were moderate increases in mean weight, BMI, and waist circumference during treatment with either sertindole or risperidone; after 12 weeks, the increase in weight was 1.3 and 1.1 kg, respectively, and after 36 weeks, it was 2.2 and 2.0 kg, respectively. From baseline to last assessment (up to 60 weeks), weight gains of 1.8 and 1.7 kg for sertindole and risperidone, respectively, were observed. Similar proportions of patients (sertindole: 17% versus risperidone: 16%) had weight increases >/=7% from baseline to last assessment. The mean changes from baseline in triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, plasma glucose and blood pressure were small and not clinically relevant in both treatment groups. No patient in either of the groups developed type 2 diabetes during the study. At last assessment, the prevalence of metabolic syndrome (International Diabetes Federation) was 17% in the sertindole group and 26% in the risperidone group and the incidence of metabolic syndrome was 7% in the sertindole group and 10% in the risperidone group. Treatment with either sertindole or risperidone did not appear to be associated with an increased comparative risk of developing metabolic syndrome. In general, the metabolic effects of sertindole and risperidone were similar.
Affiliation
University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070, Kortenberg, Belgium, marc.de.hert@uc-kortenberg.be.
Journal Details
This article was published in the following journal.
Name: European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20820795
- DOI: http://dx.doi.org/10.1007/s00406-010-0142-x
Medical and Biotech [MESH] Definitions
Penfluridol
One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.
Hiv Long-term Survivors
Persons who have experienced prolonged survival of HIV infection. This includes the full spectrum of untreated, HIV-infected long-term asymptomatics to those with AIDS who have survived due to successful treatment.
Memory, Short-term
Temporary storage of information for a few seconds to hours, as opposed to long-term memory which refers to material stored for days, years, or a lifetime.
Insurance, Long-term Care
Health insurance to provide full or partial coverage for long-term home care services or for long-term nursing care provided in a residential facility such as a nursing home.
Long-term Potentiation
A persistent increase in synaptic efficacy, usually induced by appropriate activation of the same synapses. The phenomenological properties of long-term potentiation suggest that it may be a cellular mechanism of learning and memory.
PubMed Articles
Abstract Objective: Autonomic nervous system (ANS) activity decrease has been associated with a higher risk of sudden cardiovascular and cerebrovascular disease. Thus, we explored the relationship bet...
An association is established between schizophrenia and the development of metabolic alterations including cardiovascular diseases, type 2 diabetes and obesity. Perinatal insults, such as undernutriti...
Importance of the field: Although atypical antipsychotics have beneficial efficacy and tolerance, non-adherence and partial adherence remain in patients treated for schizophrenia. Long-acting injectab...
Prediction of the outcome of short- and long-term psychotherapy based on socio-demographic factors.
Socio-demographic factors predict the outcome of short-term psychotherapy (STT) in the treatment of mood and anxiety disorders, but information on the prediction for long long-term therapy (LPP) is la...
Long-term outcome in CIDP patients treated with IVIg: A retrospective study.
BACKGROUND: The objective of this retrospective study was to describe the short- and long-term patterns of IVIg use, safety, and response to treatment in CIDP patients. METHODS: Response to therapy wa...
Clinical Trials
Effect on Metabolic Parameters of Abilify in SPR
To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for...
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.
This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with Schizophrenia.
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
